EASME

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Probiomedica combines engineering, biology, photonics and robotics, and aims to develop innovative devices for the application to health and personal care.

More than just a medical device, liberDi is an innovative all-in-one portable Digital Dialysis Clinic providing scalable, digital and safe, self-care anywhere. It provides an Intelligent Dialysis Assistant (IDA) and remote medical supervision, together creating the ultimate Digital Dialysis Clinic, allowing patients to choose Anywhere PD (Peritoneal Dialysis) as first modality. liberDi’s system is positioned to replace traditional full-service, in-clinic care with a self-care system suitable for many dialysis patients. Focused on patient care liberation and improved quality of life, liberDi allows many more people requiring dialysis to do so easily and comfortably from wherever they are, be that their home, office or on vacation. Founded in 2014 and supported by a team of world-renowned scientists, engineers and physicians, liberDi’s vision and mission have always been to find a way to free dialysis patients from the need to spend half their lives dialyzing in expensive dialysis clinics and centers. liberDi’s cutting-edge innovation is safe, patient friendly, and portable. In addition to liberating patients, it also enables clinics to optimize their economic model and improve the quality of their service while lowering costs; This creates the optimal, world’s first, 360° platform for Renal patients and caregivers alike.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Surgitate fabricates synthetic models that surgeons, medical and veterinary students, and other medical staff such as nurses and obstetricians can practice on. Their models are designed to create a realistic feel of incision, dissection, and suturing. Their cofounders are a materials engineer (Ozge Akbulut, PhD) and a thoracic surgeon (Barkın Eldem, MD). Surgitate has two investors: Farplas, leading plastic automotive parts manufacturer in Turkey, and Inovent, Turkey’s first technology commercialization/accelerator and seed funding company. They rely on expertise of Farplas in process development, molding, and painting for the mass scale production of synthetic body parts. Inovent assures that we are well-connected to our potential investors and customers; and handles business and marketing plans.

ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Cardiawave, established in late 2014 through a collaboration between the Langevin Institute and the Georges Pompidou European Hospital, specializes in developing non-invasive ultrasonic medical devices aimed at treating heart valve diseases. The company's innovative technology focuses on real-time image guidance to address conditions such as calcified aortic stenosis, minimizing thermal injury and allowing for efficient treatment by clinicians. With a commitment to advancing medical care, Cardiawave has raised over €14 million since its inception to support product development and preclinical studies, paving the way for expected clinical trials to begin. The experienced management team, recognized for its excellence, continues to drive the company's mission to improve patient outcomes in cardiovascular health.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

AMF Medical is focused on developing Sigi, an innovative patch pump designed to administer insulin with exceptional ease of use. This novel device is intended for seamless integration into closed loop systems, compatible with third-party Continuous Glucose Monitoring products and dose-calculating algorithms. The company's mission is to alleviate the therapy burden faced by individuals with diabetes, ultimately aiming to enhance their quality of life. AMF Medical was established in early 2021 as a spin-off from Advanced Microfluidics, which specializes in high-end lab equipment components that utilize related technologies.

Novagan Sàrl, founded in 2009 and based in Lausanne, Switzerland, specializes in the development and fabrication of semiconductor epitaxial wafers, particularly focusing on III-nitride materials. The company produces advanced optoelectronic components designed for high-power electronics and ultraviolet-visible applications, including new light sources based on gallium nitride (GaN) semiconductors. Novagan's products are aimed at industries such as medical imaging, displays, and projection systems, helping to transform innovative designs into functional products. The company seeks to establish long-term relationships with clients by providing timely, reliable, and cost-effective services that align with market needs.

MyoSwiss AG, founded in 2017 and based in Zurich, Switzerland, specializes in medical technology aimed at enhancing mobility for individuals with muscle weakness. The company develops innovative products such as the Myofit and Myosuit, which serve as advanced training devices for rehabilitation and physiotherapy. These devices are designed to improve the quality of life for users by providing an additional layer of muscle support, thereby enabling them to regain their mobility and independence. MyoSwiss also offers personalized training plans, intensive activity-based training, and performance tracking to enhance the effectiveness of its solutions, helping individuals with mobility impairments realize their potential for physical activity.

Stokhos started as a scientific mathematical project named REPRO with the aim to reduce ambulance response times. The potential social impact motivated the foundation of Stokhos. We at Stokhos are all very enthusiastic about mathematics and science and are tirelessly working on making the world a safer place. As their products were first developed for he medical emergency market, we have a strong affinity with the medical emergency field. All members of their team, do, for example, have valid first aid certification.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

At 3DBattery they are committed to creating the best possible products for your business, with the utmost care and quality that you truly deserve. To us, the job is not complete until we know that their customers are satisfied with the end-results. Their ultimate goal is to make it easier for you to run your business. Keep reading to learn more about their values, or contact us for more details. 3DBattery (3DB) is a start up company specializing in the design, development and manufacture of innovative energy storage solutions suitable for the emerging needs of flexible and portable electronic devices such as flexible and wearable electronics, energy harvesting devices, IoT, Surface-mount technology(SMT) and medical devices.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

BrainPatch is a neurotechnology startup focused on non-invasive brain stimulation. The company develops a computer-brain interface that assists healthcare professionals in measuring brain activity. Its platform integrates artificial intelligence, hardware, and applications, allowing developers, professionals, and patients to conduct brain simulations. This technology aims to facilitate early detection of conditions requiring non-invasive brain stimulation, ultimately aiding patients in their recovery from neurological diseases. BrainPatch recognizes that effective brain stimulation is complex and must be tailored to the individual needs of each patient.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Medfield Diagnostics AB, founded in 2005 by Mikael Persson and Andreas Fhager, specializes in the development and commercialization of diagnostic instruments utilizing microwave technology. The company focuses on advancing stroke diagnostics through its innovative products, including Strokefinder and Impending Applications. By leveraging promising research conducted at Chalmers University of Technology, Medfield Diagnostics aims to enhance the accuracy and efficiency of stroke detection and management.

EarWays Medical Ltd. is an innovative company focused on developing ear-care solutions aimed at improving the well-being of children and adults globally. The company specializes in a medical device designed for the effective removal of earwax, utilizing a patented technology that features a flexible, coated helical tip for easy navigation in the ear canal. This device is suitable for both clinicians and home users, facilitating the management and extraction of cerumen. Backed by a team of experts in bioengineering, medical devices, and ear health, EarWays Medical is well-positioned to address the medical demand for accessible and effective ear care, helping to prevent temporary hearing loss caused by earwax buildup.

Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement and analysis of the pain by facial, vocal and postural recognition.

CardiacSense is an innovative start-up on track to revolutionize the Wearable Health Industry by providing affordable, comfortable FDA & CE certified Medical Watches and Wristbands capable of continuous, long term, ambulatory and non-invasive monitoring of life critical functions including Heart Rate, Pulse Rate, Respiratory Rate, Core Temperature, Oxygen Saturation and Blood Pressure. These capabilities enable accurate real time diagnostics of medical conditions such as Heart Arrhythmias (incl. Atrial Fibrillation), Hypertension, COPD, Heart Failure, Sleep Apnea and infections (such as COVID-19).

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

TomoWave commercializes and produces innovative imaging modalities with applications in clinical medicine and preclinical research. Our proprietary technology “listens to the sound of light” to produce highly resolved images from the depth of tissues. The main targeted medical needs of TomoWave platform technology include detection and diagnostics of cancer, image guided interventions and monitoring the effectiveness of anticancer therapy and diagnostics imaging of vascular and blood related conditions. A pipeline of innovative optoacoustic and laser ultrasonic imaging technologies based on inventions made by the company founder, Dr. Alexander Oraevsky, pioneer of biomedical optoacoustics and recipient of multiple grants and awards for development of molecular imaging systems and applications. TomoWave Laboratories has the capability to generate intellectual property and develop its IP from idea to validated clinical prototypes and brings these technologies to the market place through regulatory certification.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

Gondola Medical Technologies is a Swiss company specialized in research and the development of new technologies in the fields of physiotherapy, neurological and osteoarticular rehabilitation. It has developed and brought to the market the GONDOLA™ medical device to give the AMPS treatment, a non-invasive add on therapy to treat motor symptoms in Parkinson's Disease; symptoms that best respond to the GONDOLA™ treatment are Freezing of Gait, walking, slowness of movement and balance. The GONDOLA™ device has been designed to be used at home; its use requires few minutes, and benefits remain for a period ranging from 3 to 5 days. Regular use of the device twice a week allows to maintain benefits overtime.

SurGuide is a medical device company with the goal to improve the surgical care for cancer patients. They support surgeons in their aim to achieve complete tumor removal, which is the biggest challenge in cancer surgery. Incomplete tumor removal, negatively affects patient outcome and necessitates additional treatment1. SurGuide’s technology addresses the problem that the information about the result of the operation becomes available only after several days. SurGuide’s technology will enable inspection of the resected tissue to determine if a tumor has been completely removed. The result of this inspection is reported to the surgeon, while the patient is still in the operating room. The report shows at which locations the tumor has not been completely removed. Based on this critical feedback the surgeon can decide to perform an additional resection at the indicated locations. In this way SurGuide’s technology will help to increase the rate of complete tumor resections.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

Bioengineering Laboratories (BEL) has been conceived as a young, streamlined and multi-faceted organization able to provide technical knowledge and a twenty year experience in designing, testing and producing innovative medical devices in the bioengineering industry. BEL is a pool of professional professionals able to critically address and re-elaborate the key aspects of a “modern” design in the medical field. The knowledge of the market, the openness to new clinical and surgical techniques, the curiosity towards new technologies, the application of an effective Quality System and the constant updating of the current legislative and regulatory requirements are their basis for engineering dedicated to life.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

Gogoa Mobility Robots is to develop affordable and effective wearable solutions to help humans increase capacity for movement. From neck, shoulder and lumbar support in industrial ergonomics, to health-related critical challenges our bio-mechanical experts create wearable robotics that support human movement. Gogoa's award winning "Assist-As-Needed"​ (AAN) control technology adapts to different human movements. AAN transforms the internal intention to move into actual movement. Our exoskeletons are used in physical rehabilitation and in manufacturing to increase movement capacity for workers and prevent injuries. Designed and made in Europe, Gogoa Mobility Robots has received CE Mark for Hank exoskeleton, allowing it to be sold commercially in Europe.

Chromition Limited, based in Manchester, United Kingdom, specializes in developing and supplying advanced nanoparticle solutions for various commercial applications. The company offers a range of products, including Luminspheres, which are multi-colored photoluminescent polymer nanoparticles used in bio-imaging, anti-counterfeiting, and lighting; Elecspheres, semiconductor polymer nanoparticle inks utilized in displays, electronics, lighting, solar cells, and sensors; and Dielecspheres, high-k dielectric films that allow electronic devices to function at ultra-low voltages and reduced power consumption. Founded in 2014, Chromition's technology originated at the University of Manchester and was spun out to facilitate the commercialization of innovative optoelectronic products.

Filterlex Medical Ltd. is a medical device startup focused on the cardiovascular field, specifically developing an advanced embolic protection device aimed at reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company's innovative device utilizes next-generation technology to address the limitations of existing products. It is designed to be securely positioned in the aorta, providing comprehensive embolic protection by deflecting, capturing, and removing embolic particles. This approach enables physicians to enhance patient safety during these complex procedures. Currently, Filterlex is seeking seed funding to further advance its development efforts.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

GyroGear is a multidisciplinary team composed of designers, engineers, and medical professionals focused on developing innovative solutions for individuals with hand tremors caused by Parkinson's disease and essential tremor. Their flagship product, the GyroGlove, is a wearable device that utilizes advanced aerospace-grade gyroscopes to mechanically stabilize hand tremors. By addressing this critical issue, GyroGear aims to enhance the quality of life, independence, and dignity of those affected by these conditions. The company is dedicated to providing an effective and straightforward solution for managing hand tremors, thereby improving daily functioning for its users.

Nimble Robotics designs and sells innovative medical devices for rehabilitation.

Abanza Tecnomed provides research and development of instruments and medical devices specialized in biomedical innovation in the field of sports medicine. Abanza Tecnomed is a research and development company of medical instruments and devices, specialized in biomedical innovation in the field of Sports Medicine. With the commitment to develop and offer the latest generation devices to facilitate the work of medical professionals, ABANZA Tecnomed has a multidisciplinary and highly qualified R&D&I team that guarantees the quality of innovations, and a first-class medical advisory board that certifies the precision and safety of the instruments developed.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Sedicidodici develops medical devices aimed at measuring the haemorrhagic and thrombogenic potential of patients with cardiovascular diseases and thrombotic-haemorrhagic disorders. Their tools facilitate the monitoring of anticoagulation and antiplatelet drug therapy effects, allowing healthcare providers to assess platelet activation and fibrin formation in blood samples. By predicting thrombotic events, which can lead to strokes and heart attacks, Sedicidodici's devices enhance patient care and improve health outcomes.

S.T.Stent develops a composite removable sinus stent. The stent is designed to be placed into ethmoid sinus following functional endoscopic sinus surgery (FESS) to maintain the cavity open. FESS procedure is used to treat chronic sinusitis, which is one of the most common health problems in the modern world. However a single surgery often is not enough to cure the patient, due to post surgery scarring, stenosis and middle turbinate lateralization. Their devise is designed to keep the cavity open long enough for the healing process to complete itself. Their main innovation is based on the fact that the stent can be removed at any time, based on patient decision or physician consult. Stent removal is an in-office procedure, done without anesthesia, and is minimally invasive for the patient.

MukoCell GmbH is a pharmaceutical company with headquarters in the German city of Dortmund. Complying with current Good Manufacturing Practices (GMP), MukoCell GmbH delivers products of extreme safety and quality. Their company has patented technologies in the growing field of tissue engineering, where the patient’s own cells are used in the treatment of his or her urological disorder. Current indications for the first product developed by their company include the repair of urethral strictures and hypospadias. Patients have the option of urethral reconstruction with an autologous MukoCell® cell transplant since 2010. Urethral repair with MukoCell® is a gentle alternative to conventional transplantation with native buccal mucosa.

CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and the Royal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses. CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.

NeoMedLight focuses on developing innovative medical devices that leverage phototherapy technology, specifically through the use of woven optic fibers known as the Fabric of Light (Lightex®). Originally developed by Brochier Technologies, NeoMedLight holds exclusive rights to this technology in the healthcare sector. The company initially created a fiber-optic device aimed at treating neonatal jaundice but is expanding its applications to include conditions such as mucositis, dermatitis, wound healing, and pain management. By providing a precise and consistent method of treatment, NeoMedLight aims to enhance therapeutic efficiency while minimizing side effects, ultimately improving patient outcomes across various medical fields.

Paragate Medical is an Israeli company based in Nazareth Illit that focuses on designing and developing innovative implantable devices aimed at providing continuous relief for patients suffering from congestive heart failure and fluid overload related to heart and kidney failure. The company's minimally invasive system is laparoscopically implanted and functions as a mechanical bypass to the kidneys, allowing for the effective removal of excess fluid from the body. This device offers healthcare providers a continuous and non-aggressive option for managing fluid levels, enabling patients to maintain balance in their fluid levels from the comfort of their homes.

Schepp Medtech GmbH, based in Niklasdorf, Austria, specializes in developing and manufacturing medical devices aimed at supporting patients with gait training needs. The company offers a rehabilitation machine designed for neurological therapy, addressing various conditions including stroke, paraplegia, multiple sclerosis, Parkinson's disease, infantile cerebral palsy, orthopedic and trauma syndromes, immobile geriatric patients, and polio. Additionally, Schepp Medtech is involved in the certification and ongoing support of its medical products within the rehabilitation segment.

EIO Biomedical is an innovative biotechnology company developing a medical device for the prevention of post-surgical adhesions. EIO Biomedical is an NGT3 VC portfolio company established in 2016. Located in Nazareth, Israel, the company secured financing of 3M NIS from NGT3 VC (www.ngt3vc.com ) and the Israeli Office of Chief Scientist (OCS).

More than just a medical device, liberDi is an innovative all-in-one portable Digital Dialysis Clinic providing scalable, digital and safe, self-care anywhere. It provides an Intelligent Dialysis Assistant (IDA) and remote medical supervision, together creating the ultimate Digital Dialysis Clinic, allowing patients to choose Anywhere PD (Peritoneal Dialysis) as first modality. liberDi’s system is positioned to replace traditional full-service, in-clinic care with a self-care system suitable for many dialysis patients. Focused on patient care liberation and improved quality of life, liberDi allows many more people requiring dialysis to do so easily and comfortably from wherever they are, be that their home, office or on vacation. Founded in 2014 and supported by a team of world-renowned scientists, engineers and physicians, liberDi’s vision and mission have always been to find a way to free dialysis patients from the need to spend half their lives dialyzing in expensive dialysis clinics and centers. liberDi’s cutting-edge innovation is safe, patient friendly, and portable. In addition to liberating patients, it also enables clinics to optimize their economic model and improve the quality of their service while lowering costs; This creates the optimal, world’s first, 360° platform for Renal patients and caregivers alike.

LifeTag is a Portuguese technology startup that specializes in the research and development of non-invasive diagnostic technologies aimed at evaluating metabolism and diagnosing various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. The company has developed a diagnostic marker that facilitates non-invasive health monitoring, particularly focusing on intestinal permeability to enhance the accuracy of chronic metabolic disease diagnoses. By providing healthcare professionals with effective tools to assess patients without causing discomfort or side effects, LifeTag aims to improve health outcomes and streamline the diagnostic process.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

Olfactomics is a Finnish university-based spinoff company focused on advancing surgical tissue assessment technology, particularly in breast-conserving lumpectomies. The company has developed innovative energy-based surgical instruments that analyze surgical smoke, which contains critical information about the operated tissue. This real-time analysis enhances the surgeon's situational awareness during procedures, allowing for the detection of cancerous tissue at margins that might otherwise be overlooked. By improving the accuracy of tumor removal in a single operation, Olfactomics aims to minimize the resection of healthy tissues and reduce the likelihood of costly re-operations.

Sone Health is an Italian company focused on enhancing the traditional stethoscope by developing an innovative add-on device that improves the capture of internal body sounds. This device converts acoustic signals from standard stethoscopes into digital data, which can then be transmitted to IoT devices. By facilitating telemedicine, Sone Health enables healthcare professionals to share vital sound data with specialists through a mobile application and web platform, thereby improving the accuracy of initial diagnoses and supporting remote patient monitoring. The company has established a patent portfolio, with a patent already approved for nationalization in Europe and the USA, reflecting its commitment to advancing medical technology. Backed by a management team with robust training in business development and experience in the Silicon Valley ecosystem, Sone Health is positioned to make significant contributions to preventive diagnosis and remote healthcare services.

Fesia Technology specializes in developing advanced medical devices that utilize functional electrical stimulation for rehabilitation therapy aimed at individuals with neuromuscular diseases and injuries. The company has created an innovative system featuring a matrix-arranged electrode, which enhances the effectiveness of functional stimulation. One of its notable products, Fesia Walk, is designed specifically for patients experiencing foot drop and represents the first offering of this new generation of devices. Fesia's commitment lies in improving the quality of life for patients and providing healthcare professionals with cutting-edge technologies to support various stages of the rehabilitation process, particularly for those recovering from strokes and other central nervous system conditions.

Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of allowing more physicians to treat more patients while improving surgical outcomes for patients. The Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.

Damavan Imaging was founded in December 2014 in Troyes (F) as a SAS with three initial patents. In July 2015, Damavan has won a 4 years research grant from « Investissements d’avenir »: (Investments for the Future Programme conducted by ANDRA), “Temporal” to develop a Compton camera based on temporal imagers. In October 2016 Damavan issued the first temporal imager based ion digital Si-PM: temporal Delta. In October 2018 Damavan issued Temporal δ V2 the first temporal compton camera based CeBr3 detectors with exceptional Signal/Noise and good angular résolution.

Allium Medical Solutions Ltd. is a publicly traded company (TASE: ALMD) which develops, manufactures and markets minimally invasive products internationally. These innovative products serve the need for minimally invasive interventions benefiting the patient by improving their recovery process and shortening it. Allium Medical Solutions' products are used by physicians to treat a wide range of diseases and patients worldwide.

Usono is a developer of innovative medical devices aimed at enhancing the application of ultrasound technology in clinical settings. The company has created an ultrasound stimulation device that facilitates the stable fixation of ultrasound transducers on patients' bodies during surgical procedures. This technology allows for dynamic monitoring and improves the efficiency of cardiology ultrasound procedures by enabling hands-free operation. Usono's devices are particularly beneficial for long-term and stress echo measurements, pacemaker optimization, and monitoring in heart catheterization labs and intensive care units. By addressing the challenges of traditional ultrasound applications, Usono significantly improves the usability and effectiveness of ultrasound in various medical contexts.

ViVO Smart Medical Devices is a design-to-manufacturing company and has an exclusive worldwide license for a novel pupil diagnostic device called a Pupiloscope – an innovative hand-held medical device enabling real-time detection, assessment and monitoring of pupil reactivity of patients with head trauma.

BluSense Diagnostics specializes in developing innovative blood testing devices aimed at diagnosing infectious diseases. The company's technology utilizes a nanotechnology biosensing method, allowing for accurate results from just a single drop of blood. This consumer-oriented device enables individuals to monitor and manage virus outbreaks effectively. By integrating advanced Scandinavian bioengineering with high-quality Taiwanese hardware and software engineering, BluSense has established a breakthrough diagnostics system that addresses the pressing need for efficient infectious disease testing.

Founded at 1976, Singer Instruments & Control is a privately owned engineering company, expert in design, development and manufacturing of electro-mechanical components and systems such as LVDTs, inclinometers, transducers and other various sensors. In addition to their off-the-shelf and customized line of products, Singer Instruments & Control holds a strong, experienced development team. They specialize in providing a solid engineering house for many startup companies, developing dozens of diverse products in the medical devices industry, the military industry and general industry. At Singer-Instruments & Control Ltd. their strengths include designing and manufacturing miniature and accurate transducers and sensors, comprising technologies such as winding 0.0004 inch (0.01 millimeters) diameter wires, complex assemblies, robotic systems, plastic molded electronic parts and vacuum potting.

Glucostratus Ltd develops innovative solutions for remote monitoring of blood glucose levels, primarily targeting patients with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company provides a cloud-based platform that captures blood glucose data via mobile technology, enabling patients to share their results with healthcare providers. This system allows professionals to set personalized targets and receive automated alerts regarding any deviations, facilitating effective remote monitoring of insulin treatment. Additionally, Glucostratus offers a digital solution for diagnostic testing and generates comprehensive reports in accordance with treatment guidelines. Their services include a user-friendly IoT solution designed for elderly diabetics, ensuring accessibility for those with limited technological skills and addressing the growing needs of the home care sector.

PixCell Medical Technologies develops, produces, and markets portable medical diagnostic products for point of care testing. PixCell's products are based on its innovative Viscoelastic Focusing (VEF) technology and single use cartridges that enable rapid, accurate and simple blood sampling and analysis. Results are displayed within minutes in an easily readable format. PixCell's mission is to make tests currently restricted to the laboratory more accessible, easy to use and affordable.

Lisapharma S.p.A., founded in 1925 and based in Erba, Italy, specializes in the manufacture of sterile injectable drugs, non-sterile liquids, semisolids, medical devices, and veterinary products. Operating in over 40 countries, the company plays a significant role in the global pharmaceutical market. Lisapharma's manufacturing facility adheres to Good Manufacturing Practice (GMP) standards, ensuring compliance in both domestic and international markets. The company holds various Marketing Authorizations for its internally produced products and also serves as a contract manufacturer for both Italian and multinational clients. In 2019, Lisapharma became a subsidiary of Shandong Sito Bio-technology Co., Ltd., following its acquisition by Italian private equity funds in 2015.

Marsi Bionics specializes in the design, manufacture, and sale of modular robotic orthoses aimed at enhancing clinical rehabilitation and mobility assistance. The company's innovative modular technology, ARES, allows for the development of self-adaptive gait exoskeletons, which can be tailored to individual users' physiological needs. Their product range includes the MAK active knee orthosis, which received CE marking in April 2020, the ATLAS pediatric exoskeleton, which became CE marked in the first half of 2021, and the STELO exoskeleton designed for adults. Marsi Bionics focuses on providing solutions for patients with walking disabilities resulting from neurological disorders and musculoskeletal complications, enabling them to regain mobility and independence.

ProArc Medical Ltd. is a medical device startup based in Misgav, Israel, founded in 2010. The company focuses on developing innovative and minimally invasive devices for urology, specifically targeting lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Its flagship product, the ClearRing system, features a unique prostatic reshaping device that employs a specialized delivery system with a nitinol implant shaped like an arc. This design aims to enable effective treatment for patients suffering from LUTS due to BPH, providing a clinically effective solution for healthcare providers.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

NeuroPsyCAD provides clinicians with patient-personalized reports for early and accurate diagnoses of neuropsychiatric disorders. NeuroPsyCAD's analysis pipeline is automated, with a report being produced in a few hours since they receive the patient's data. Given the high sensitivity and specificity of our approach, subtle changes in brain structure and function can be detected early and accurately at the disease onset, enabling clinicians to diagnose and, thus, treat patients earlier and with more confidence. NeuroPsyCAD aims to replace the so far relatively subjective and metrics-independent practice of psychiatry and neurology with a more quantified, objective, accurate, and personalize one.

Glycobond specializes in the development and production of proprietary carbohydrate-binding reagents aimed at enhancing diagnostics for liver diseases and cancer. The company has created HepaCheC™, an ELISA-based assay that identifies abnormal and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein primarily produced in the liver. This innovative assay allows for analysis using simple blood samples, leveraging a patented fucose-binding protein known as Mono-F. Glycobond's approach has demonstrated promising results in monitoring patients at risk of developing hepatocellular carcinoma (HCC), offering a valuable tool for physicians in diagnosing and managing liver conditions.

NORAKER specializes in the design, production, and marketing of synthetic and bioactive biomaterial-based implantable medical devices for bone substitution and osteosynthesis. The company has been able to establish a close and regular collaboration with health professionals to meet a demanding market, with one goal: to improve the comfort of patients. Noraker has built its development on a strategy of differentiation through innovation, using bioactive glass, active ceramic second generation, in the design of its medical devices.

The company develops and manufactures state of the art systems integrating electronics, mechanics, optics, software and algorithm development in the fields of medical equipment, media inspection, telecommunications, printing, audio and lab equipment. Company services range from presenting solutions for particular problems to supplying complete integrated systems including concept definition, design and development, PCB design, project management, logistics, purchasing and manufacturing. Prise Systems, by the expertise of the team, is providing creative and efficient solutions to hard-to-solve problems. The company operates by bringing together teams of highly experienced professionals in multiple complimenting fields, thus placing the company in a unique position to serve various needs of high-tech companies.

Rubedo Sistemos (a.k.a. Rubedos®), a Lithuania-based pioneer company of mobile robotics solutions, develops 3D visual perception and navigation technology for free ranging vision guided robotics applications in various industries, including manufacturing, material handling, and healthcare. The company is well regarded for its FDA-compliant robotic precise tumor targeting solution designed exclusively for an image guided radiation therapy product of Elekta, a medical device manufacturer listed on NASDAQ OMX NORDIC.

Ostoform is a spin-out medical device company from the University of Limerick, Ireland with a range of patented technologies, and the potential to scale, becoming a global leader in the area of ostomy skin health.

EBERS Medical Technology SL is devoted to the development of equipment for cell and tissue culture. They are focused in creating new and innovative products which help the users to improve their protocols by providing new tools able to simplify research tasks or offering technical solutions which make easier to develop new experimental set-ups in simple and efficient way. EBERS manufactures, markets and service products for research institutions in several countries by means of its distributors network and also provides extensive development services of bespoke culture chambers for tissue engineering.

AB-BIOTICS is a Spanish biotech company focused on research, development, protection and distribution of its own biotechnological solutions. It aspires to set a standard in the European biotechnology industry for both value and profitability. The company offers probiotic products, including cardio metabolic products comprising AB-LIFE, AB LIFE Forte, AB-LIFE Plus, LipiGO, and AB-Fortis; oral care products that include AB-Dentalac, AB-Dentalac Pro, AB-Dentalac Junior, AB-Dentisanium, and Avantbise; pediatric products, such as AB-Kolicare, AB-Digest Kids, and IronKid; i3.1 gastrointestinal product; gynecology and urological products consisting of AB-Intimus, AB-Intimus cosmetic line, IronGest, Ironlact, and AB-Cyscare; and dermatology and immunology products, which include AB-Immuno and AB-Sakei 65. It also provides genetic tests for behavioral health, pain medicine, fertility, and urology, as well as lab services. AB-Biotics, S.A. was founded in 2004 and is based in Barcelona, Spain.

Innerspec Technologies specializes in designing and commercializing non-destructive testing systems, positioning itself as a leader in high-power ultrasonics and Electro-Magnetic Acoustic Transducer (EMAT) technology for the inspection of metallic parts and components. Headquartered in Forest, Virginia, the company also maintains regional offices in Spain and China. Innerspec provides a range of products and services, including fully automated turnkey solutions and advanced ultrasonic equipment, to meet the needs of its customers in various commercial applications.

Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, providing innovative AI-based image processing technologies. Its products, utilized by pharmaceutical companies and research teams globally, focus on extracting quantitative information from radiological images. Quibim Precision®, the company's whole-body imaging ecosystem, supports a variety of applications, from disease detection to monitoring the effectiveness of new treatments. By employing an AI-first approach, Quibim enables partners to accurately identify pathologies across different body parts and imaging modalities, ultimately enhancing the diagnosis of high-incidence illnesses and assessing treatment outcomes. This commitment to leveraging advanced imaging biomarkers contributes significantly to improving human health.

Thomas Medical is a CRI company manufactures single-use medical devices and accessories for women’s health. The company manufacturesHS catheters and procedure trays, uterine manipulators (UMI), injectors, endometrial samplers, IUI catheters and LEEP/LLETZ electrodes. Our products are used in thousands of hospitals, surgery centers, radiology/imaging centers, fertility/IVF clinics and OB/GYN practices throughout the world. Thomas Medical - World’s Best Source for Quality OBGYN Instruments provides high quality products at reasonable prices i.e. Gas Sampling Lines, Curettes, UMI, Endometrial Biopsy, Hysterosalpingography and other surgical instruments with satisfaction guarantee

QuantumWise specializes in developing commercial software for atomic-scale modeling of nanostructures. The company offers simulation tools, including toolKit and virtual nanolab, which are designed to assist industries such as manufacturing and healthcare. These tools provide users with an intuitive interface for reliable and efficient materials modeling, allowing for improved decision-making and project design. QuantumWise's solutions are crafted from advanced methodologies and tailored to meet the specific needs of its customers, ensuring a robust support system for users engaged in complex material design and analysis.

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.

EOS S.r.l. (Effective Optical Systems, www.eosinstruments.com) delivers a new generation of scientific instruments and technological solutions for the classification and characterization of particles and particle mixtures in biological, industrial and environmental heterogeneous fluids. Implementing strategies for particle analysis in complex fluids via light scattering, EOS provides CLASSIZER™ cutting edge family of platforms for the multiparameter analysis at single particle level via the key enabling SPES (Single Particle Extinction and Scattering) patented technology. CLASSIZER™ devices classify single particles on the basis of their optical properties in liquids and aerosols: discriminates particles in heterogeneous samples; enables advanced product formulation by monitoring the particle stability and behaviour in real complex fluids (aggregation, degradation, wetting); boosts QC operations measuring even in presence of impurities, synthesis residues, bubbles and immiscible liquid droplets (typically no filtration or purification is required). CLASSIZER™ platforms are powerful solutions for product R&D and Quality Controls in life sciences, pharmaceuticals, cosmetics, food and beverages, inks and pigments, agrochemicals, lubricants and abrasives and environmental sciences.

PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

ECH Elektrochemie Halle GmbH is a developing and producing company. They develop and produce standard analyzers as well as tailor-made metrology for analytical problem. In addition to standard products, they also produce individual solutions in the field of analytics. They also offer services in terms of: creation of customer-specific control and regulation systems in combination with sensor technology, development and production of analytical modules for third-party devices, and manufacture and sale of measuring instruments for laboratory, process and mobile on-site analysis.

IBEX Innovations Limited specializes in developing and commercializing advanced X-ray detector technology that provides high sensitivity materials information using standard X-ray systems. Founded in 2010 by Dr. Gary Gibson and based in Sedgefield, United Kingdom, the company has created the IBEX multi absorption plate (MAP) technology, which enhances traditional detectors by integrating materials information while maintaining key performance characteristics like speed and spatial resolution. IBEX's solutions are utilized across various sectors, including healthcare for bone mineral density assessment, electronics inspection, food safety, and security applications. The company collaborates with academic institutions, such as the Mathematics Department at Durham University, and maintains partnerships with healthcare organizations to validate its technology in medical imaging. Supported by venture capital and grants, IBEX Innovations continues to advance its technology to transform standard X-ray imaging into powerful diagnostic tools.

Optofluid Technologies develops sensors for real-time and on-line dialysis quality monitoring.

Vita Sentry Ltd. has developed a non-invasive optical technology, which for the first time measures the inner diameter, cross section, degree of change, and level of stiffness for small blood vessels - arterioles.

DesignPro is a provider of precision automation and machine build services to a variety of industries such as pharmaceuticals, medical devices, aviation, automotive, cosmetics and renewable energy. Based in County Limerick, Ireland the company has developed a reputation as a creative and highly professional partner to some of the world’s largest multinationals. Providing a complete turnkey solution, their services include: problem analysis, design, prototyping, build, installation and maintenance.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.